Last reviewed · How we verify
NCT06682299
Maintenance TMS in Treatment Resistant Depression
NA trial testing Transmagnetic Stimulation in Treatment Resistant Depression (TRD) in 30 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Austin Messner |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 17 April 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transmagnetic Stimulation
- Electroconvulsive Therapy
Conditions studied
- Treatment Resistant Depression (TRD) — all drugs for Treatment Resistant Depression (TRD) →
Sponsor
Austin Messner
Who can join
Adults 18 to 65, any sex, with Treatment Resistant Depression (TRD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder. This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06682299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Treatment Resistant Depression (TRD)
Currently open trials in the same condition.
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06773949 — Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression · NA · recruiting
- NCT07264452 — Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst St · NA · recruiting
- NCT06668571 — Intravenous Ketamine for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06812923 — TACS on High-inflammatory and Refractory Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06682299 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Austin Messner
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06682299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing